首页> 美国卫生研究院文献>British Journal of Cancer >Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.
【2h】

Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.

机译:对照治疗小细胞肺癌的十二个疗程和六个疗程的化疗。肺癌工作组向医学研究委员会报告。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A total of 497 patients with histologically or cytologically confirmed small-cell lung cancer were prescribed initial treatment with six courses of etoposide, cyclophosphamide, methotrexate and vincristine at 3-week intervals. Patients with limited disease (74% of the total) also received radiotherapy (40 Gy in 15 fractions in 3 weeks) to the primary site between courses 2 and 3. At the end of this initial treatment, 265 patients still in complete or partial response were randomly allocated to six further courses of maintenance chemotherapy (M series: 131 patients) or to no maintenance chemotherapy (NoM series: 134 patients). Response, as assessed 3 weeks after the second course of initial chemotherapy, was achieved in 85% of the 264 patients assessed, a complete response in 11%. The median survival period from the date of start of chemotherapy was 39 weeks; 154 (31%) of the patients were alive at 1 year, 29 (6%) at 2 years and 17 (3%) at 3 years. The patients' general condition and extent of disease pretreatment correlated significantly with survival. Among the 131 M and 134 NoM patients there was no overall survival advantage to either series (P = 0.27, log rank test), although in 99 patients who had a complete response to initial chemotherapy as assessed at the time of randomisation there was a suggestion that survival was longer in the M series (P less than 0.05, log rank test), the median survival periods from the date of randomisation being 42 weeks for the M and 30 weeks for the NoM patients. Maintenance chemotherapy was associated with additional toxicity and a poorer quality of life as assessed intermittently by clinicians and daily by patients. In conclusion, no worthwhile clinical advantage was achieved by the policy of continuing chemotherapy beyond six courses, except possibly in patients with a complete response to the initial six courses.
机译:经组织学或细胞学确认的小细胞肺癌共497例患者接受了三疗程的依托泊苷,环磷酰胺,甲氨蝶呤和长春新碱六个疗程的初始治疗。疾病受限的患者(占总数的74%)还接受了放射疗法(3周内15个分数中的40 Gy)至疗程2和3之间的主要部位。在此初始治疗结束时,有265例仍处于完全或部分缓解的患者被随机分配到另外六个疗程的维持化疗(M系列:131例患者)或无维持化疗(NoM系列:134例)。在接受初次化疗的第二个疗程后3周评估的反应,在264名接受评估的患者中达到了85%,完全缓解率为11%。从开始化疗之日起中位生存期为39周; 154名(31%)患者在1年时还活着,29(6%)在2年时还活着,17(3%)在3年时还活着。患者的一般状况和疾病预处理的程度与生存率显着相关。在131 M和134 NoM患者中,这两个系列均没有总体生存优势(P = 0.27,对数秩检验),尽管在随机分组时评估的对初始化疗完全反应的99位患者中,有建议在M系列中生存时间更长(P小于0.05,对数秩检验),从随机分组之日起中位生存期为M组为42周,NoM患者为30周。维持化疗与额外的毒性和较差的生活质量相关联,这是由临床医生和患者每天进行的间歇评估。总之,继续化疗超过六个疗程的政策没有取得任何有价值的临床优势,除非可能是对最初六个疗程有完全反应的患者。

著录项

  • 期刊名称 British Journal of Cancer
  • 作者

  • 作者单位
  • 年(卷),期 1989(59),4
  • 年度 1989
  • 页码 584–590
  • 总页数 7
  • 原文格式 PDF
  • 正文语种
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号